Author

H. Taniguchi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:differential expression· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Chow· 1 shared A. Koch· 1 shared A. Liss· 1 shared A. Manyard· 1 shared A. Matsui· 1 shared A. Quintanal-Villalonga· 1 shared B. Gjeta· 1 shared B. Houck-Loomis· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Chow

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

IFNA pathway drives the more aggressive phenotype of KRASG12D-mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation

D. G. Duda, K. Inoue, D. H. Schanne, A. Matsui, P. Lei, S. Klein, S. Aoki, H. Taniguchi, H. Kikuchi, J. Chen, Z. Liu, S. Q. Tsai, T. C. Schmidt, M. Iwasaki, G. Geidel, , N. Bardeesy

The paper shows that the IFNA pathway promotes aggressive KRASG12D-mutant pancreatic ductal adenocarcinomas through IFNAR1/STAT3 activation and identifies IFNAR1 inhibition as a potential therapeutic strategy.

bioRxiv · Jun 29, 2022 · PreprintCancer Biology

Reconstructing cell interactions and state trajectories in pancreatic cancer stromal tumoroids

R. Okuda, B. Gjeta, D. Popovic, A. Manyard, Q. Yu, Z. He, M. Santel, M. Seimiya, S. Morinaga, Y. Miyagi, T. Yamaguchi, Y. Ueno, H. Taniguchi, B. Treutlein, G. Camp

This study develops a stromal tumoroid model of pancreatic cancer to investigate cell interactions and state changes, identifying key factors like SDC1 and PPARG that influence cancer cell behavior and therapy response.

bioRxiv · Feb 14, 2022 · PreprintCancer Biology

Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation

A. Quintanal-Villalonga, H. Taniguchi, M. A. Hasan, F. Meng, F. Uddin, M. Donoghue, H. H. Won, S. S. Chavan, J. M. Chan, M. Ciampricotti, A. Chow, M. Offin, J. C. Chang, J. Ray-Kirton, J. Egger, , T. Sen

The paper identifies molecular mechanisms of neuroendocrine transformation in lung cancer using multi-omic analysis of tumors and clinical samples.

bioRxiv · Dec 2, 2020 · PreprintCancer Biology

Recombinant production of active microbial transglutaminase in E. coli using self-cleavable zymogen with mutated propeptide

R. Sato, K. Minamihata, R. Ariyoshi, H. Taniguchi, N. Kamiya

This paper describes the production of active microbial transglutaminase in E. coli using a modified zymogen with mutations in the propeptide to achieve pure, active enzyme.

bioRxiv · Feb 25, 2020Bioengineering